硫福拉对子精液长期储存的作用
Serkan Ali Akarsu1, İbrahim Halil Güngör2, Aslıhan Çakır Cihangiroğlu2
1Department of Reproduction and Artificial Insemination, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
Animal reproduction
|June 9, 2023
概括
硫福拉 (SFN) 补充剂改善了子精液的冷保存. 10微米的SFN剂量增强了精子的运动性,减少了损伤,并在冷和解后保持了线粒体潜力.
科学领域:
- 生殖生物学 生殖生物学
- 低温生物学 低温生物学
- 动物科学动物科学
背景情况:
- 动物生殖质的冷保存对于遗传资源的保存至关重要.
- 优化冷保护剂对于最大限度地减少冷和解过程中的损伤至关重要.
- 硫氨酸 (SFN) 是一种具有已知的抗氧化特性的天然化合物.
研究的目的:
- 评估硫黄 (SFN) 作为子精液冷保存中的补充剂的疗效.
- 为了确定最佳的SFN度,以改善经解后的精子质量.
主要方法:
- 子精液被分为不同SFN度 (0,5,10,25,50μM) 的组.
- 评估了精液参数,包括运动性,活力,体完整性,线粒体膜潜力,亡和ROS.
- 分析是在4°C和冷解周期后进行的.
主要成果:
- 在4°C时没有观察到任何显著差异.
- 在解后,10微米SFN组表现出最高的总运动率,渐进运动率和快速的精子率.
- 10微米SFN组也显示了最低的体损伤率,死亡精子,亡和ROS,以及高的线粒体膜潜力.
结论:
- 硫福拉补充剂,特别是10μM,在冷保存后显著提高了子精液的质量.
- 10μM SFN 改善精子活力,减少冷解过程中的氧化应激和亡.
- 作为改善哺乳动物精液冷保存协议的有益添加剂,SFN具有前景.
相关概念视频
Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
Drug Product Stability
The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.


